Research Use Only. Not medical advice. Not intended to guide human self-administration. FDA-approved label is included for reference only.
Tirze Protocol Reference
FDA-approved label framework, U-100 arithmetic reference, off-label physician context, and sourcing notes.
Sourced Protocol Frameworks
Source: FDA GLP2TZ/GLP2TZ Label / Joseph Physician PracticeProtocol philosophy: Start at FDA-labeled initiation dose (2.5 mg weekly). Escalate no faster than the labeled schedule. Off-label sub-2.5 mg approaches are not a labeled standard.
FDA START2.5 mg SC weekly for 4 weeks. Labeled initiation dose for both GLP2TZ and GLP2TZ.
ESCALATIONIncrease by 2.5 mg every 4 weeks as tolerated, per FDA label. Target dose depends on indication and response (5–15 mg).
JOSEPHOff-label sub-2.5 mg ‘microdosing’ described in physician practice. Not an established labeled regimen — not attributed to any clinical standard.
U-100 Calculation Reference
Example Calculation — 20 mg Research Vial at 10 mg/mL
VIAL CONTENT
20 mg
EXAMPLE VOLUME
2.0 mL BAC water
CONCENTRATION
10 mg/mL
2.5 mg DOSE
0.25 mL = 25 units U-100
5.0 mg DOSE
0.50 mL = 50 units U-100
STORAGE
Refrigerated 4°C
⚠ Arithmetic example only. Not a preparation instruction. Actual reconstitution depends on your specific vial strength. The FDA-approved GLP2TZ/GLP2TZ products are supplied in single-dose autoinjectors — this calculation applies only to research vial contexts.
Cycle & Reassessment
| Parameter | Framework | Source |
|---|---|---|
| FDA approved cycle | No on/off cycle — chronic use as indicated | FDA label |
| Escalation interval | Every 4 weeks as tolerated | FDA label |
| Off-label cycle | Not established — physician practice varies | Off-label context |
| Reassessment | 4-week intervals during titration per label | FDA label |
Pairing & Sequencing
| Compound | Relationship | Sequencing |
|---|---|---|
| AOD | Lipolytic add-on in physician practice | Not validated — physician practice only |
| MOTS-c | Mitochondrial/metabolic support | Physician practice context |
| Tessa | GH axis concurrent — physician discussion | Context-dependent |
Evidence Status
| Category | Status |
|---|---|
| Overall | FDA-approved (T2D + obesity) / off-label investigational |
| Phase III data | SURMOUNT + SURPASS trials — up to 22.5% mean weight loss at 72 weeks |
| FDA status | Approved — GLP2TZ (T2D) and GLP2TZ (obesity) |
| WADA status | Prohibited |
Source Tirze at Forge Scientific
Third-party tested, HPLC + Mass Spec verified, lot-specific COA. Ships same day — Fort Worth, TX.